Printer Friendly

Evaluation of serum brain-derived neurotrophic factor levels in children with attention deficit hyperactivity disorder: preliminary data/ Dikkat eksikligi ve hiperaktivite bozuklugu (DEHB) tanisi olan cocuklarda serum beyinden koken alan norotrofik faktor (BDNF) seviyelerinin degerlendirilmesi: oncul bulgular.


Attention deficit hyperactivity disorder (ADHD) is an important psychiatric illness affecting 5% of children globally. It is characterized by core symptoms like hyperactivity, attention deficit and impulsivity far beyond the developmental levels and has negative impact on quality of life of both patients and their family members (1).

Even though the pathogenesis of ADHD is still greatly unknown, evidences from different research studies point out primarily the dopaminergic system (2). Molecular genetic studies show that the genetic abnormalities in D4, D5 receptors and the dopamine transporter gene are related to ADHD (3).

As a member of the neurotrophin family, brain-derived neurotrophic factor (BDNF) is the most widely expressed neurotrophin in the brain (4). Preclinical preliminary studies have shown that BDNF plays an important role in the survival and differentiation of the dopaminergic neurons in the midbrain (5,6). Besides, it has been shown that BDNF prevents the spontaneous deaths of dopaminergic neurons in rat's mesancephalic culture (7), prevents neurotoxic effects (5) and protects nigrostriatal dopaminergic neurons from neurotoxicity (8). Since the midbrain dopaminergic system is very important in the ADHD pathogenesis (9), it was proposed that reduced midbrain BDNF activity may cause midbrain dopaminergic dysfunction and that this may lead to ADHD (10).

Psychostimulants can increase the release of dopamine and norepinephrine in the midbrain by various mechanisms. It has been shown that BDNF modulates dopamine release. It has been seen that the dopamine release induced by the psychostimulants was repressed by BDNF and due to this, BDNF was thought to be related to psychostimulant-induced dopamine release (11). Also, it has been demonstrated that the psychostimulants and antidepressants commonly used in the treatment of ADHD increase central BDNF (12,13). These findings showed that central BDNF activity has an important place in the treatment of ADHD (10).

The dopamine transporter (DAT) has a key role in terminating dopaminergic neurotransmission and genetic, pharmacological and neuroradiological evidences point out that DAT is related to the pathogenesis of ADHD (2). Since the DAT knockout mice show characteristics of ADHD, including hyperactivity and cognitive impairments, a preclinical model for ADHD was proposed (14). Fumagali et al. (2003) found that the DAT knockout mice had reduced expression of BDNF gene in their frontal cortices (15).

Mice with BDNF ablation die soon after birth and show abnormalities both in peripheral and central tissues. In mice with only one functional BDNF allele (heterozygous null mutant's mice, BNDF +/-) reduced BDNF gene expression, and locomotor hyperactivity has been detected (16). In rats which BDNF was only eliminated in the brain after birth using the cre-loxP recombination system technology, it was shown that hyperactivity, locomotor activity and aggression were increased in "conditional knockout mice" exposed to stress when compared to controls (17).

Currently, there is only one study that investigates ADHD and peripheral BDNF levels. In that study, ADHD patients with no former history of medication were compared to healthy controls and the plasma BDNF levels were found to be significantly higher in the children with ADHD. Indeed, the plasma BDNF levels showed a positive correlation with the severity of attention deficiency symptoms. The authors interpreted the increase in the BDNF levels was as a compensatory response to dopaminergic and serotonergic dysfunction proposed in the pathogenesis of ADHD (18).

BDNF is found in both brain and peripheral blood. Serum levels of BDNF have been found to be higher than plasma levels (19). In addition, human platelets contain BDNF (20). Pan et al. investigated the ability of BDNF to cross the blood-brain barrier and they concluded that intact BDNF in the peripheral circulation crosses the blood-brain barrier by a high-capacity (21). Although, Shim et al. suggested that there is an increase of plasma BDNF levels in untreated children with ADHD (18), the reliable measurement source of the peripheral blood BDNF is still unknown. Since BDNF is known to cross the blood-brain barrier in both directions, circulating BDNF might originate from neurons and glial cells of the brain (21). Accordingly, serum levels of BDNF have been found to be 200-times higher than plasma levels (19). However, so far there has been no study on serum BDNF levels in children diagnosed with ADHD. In the present study, therefore, we examined the serum levels of BDNF in both children with drug-naive ADHD and normal controls. We then explored whether there are any correlations of serum BDNF levels with clinical subtypes and comorbid conditions of ADHD.

In this study, we investigated the differences in serum BDNF levels of untreated children with ADHD diagnosis and healthy controls as well as whether there was a correlation between the serum BDNF levels and severity of ADHD symptoms.



30 children with ADHD and 31 healthy controls were recruited. The group of children diagnosed with ADHD was chosen from the children referred to the Child and Adolescent Psychiatry Department at Dokuz Eylul University, School of Medicine. The cases consisted of children between 6 and 12 years with no former history of psychiatric medication and medical illnesses. Children with history of seizures, epilepsy, progressive neurological illnesses, pervasive developmental disorders, substance abuse disorders, psychotic disorders, mood disorders, mental retardation (IQ below 70) and a history of severe head trauma (within the last 1 year) were excluded. Thirty-one healthy children, living in the same area with similar demographic characteristics (age, gender, mother's age, mother's education, and number of siblings) and without any acute or chronic medical problem, were included in the study as a control group. They were chosen from children that met no criteria for a psychiatric diagnosis after a careful evaluation by a specialized child and adolescent psychiatrist. The Wechsler Intelligence Scale for Children-Revised (WISC-R) was applied to the control group and children with IQ below 70 were excluded. In addition, children with chronic medical and neurological illnesses were excluded. The study protocol was approved by the institutional ethics committee of Dokuz Eylul University and all parents gave their informed consents for their children to participate in the study and children gave assent.


For all children diagnosed with ADHD, psychiatric diagnoses were made by an experienced child and adolescent psychiatrists using the Kiddies Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL) (22) that was prepared according to the DSM-IV TR criteria (23). Besides, parents were asked to fill out the Child Behavior Checklist (CBCL) for 4-18 yrs (24) and the ADHD Rating Scale-IV (25). Teachers were asked to complete the Conners' Teacher Rating Scale (26). The symptom severity of ADHD was measured by the Clinical Global Impression (CGI)-ADHD-severity scale.

Collecting Blood Samples and BDNF Measurement Method

For the measurement of BDNF, blood samples (10 mL) were collected from the children at morning hours between 09.00 and 10.00 a.m. after at least 12 hours of fasting. The samples were collected in tubes without anticoagulants and were immediately sent to the laboratory where they stayed at room temperature for 30 minutes. Then, the samples were centrifuged at 3000 g for 10 minutes and the serums collected were pipetted to the Eppendorf tubes with 2-3 layers. The samples were stored in the deep freezer at -85[degrees]C until the day of analysis.

For the measurement of BDNF, commercial sandwich ELISA kit was used (Millipore, Chemikine, and CYT306). The study was conducted after preliminary studies to determine appropriate dilution percentages and according to the manufacturer guidelines. After the serum samples were diluted by 1/7-1/10, the diluted sample (100mL) was pipetted to 96-spaced microplates covered with monoclonal antibodies against human BDNF protein produced in rats. The plates were incubated at 4[degrees]C for 17 hours. After incubation, all factors in the serum that were not bound were removed by four subsequent wash-outs. The wash-outs were carried out by automatic equipment. Then, biotin-bound BDNF antibodies (100 mL) were added to the spaces, incubated at room temperature for 2 hours and washed four times. Then, 100 mL horseradish-peroxidase (HRP) enzyme conjugated with streptavidine was added to the spaces. After an hour of incubation, the washing procedure was repeated as defined above. After this process, 100 mL peroxidase substrate tetramethyl benzidin (TMB) was added to each space, was kept at room temperature for 15 minutes and then, 100 mL HCL solution was added to each space to stop the reaction, and the absorbance of the reaction was read at 450 nm. By using recombinant BDNF standards for the samples in the same way, a calibration graphic was constructed and the BDNF values in the samples were defined quantitatively.


Statistical evaluations were performed using SPSS version 11.0. For the comparison of categorical variables, chi-square test and the Fisher's exact chi-square test, when needed, were used. Continuous variables were compared by using independent sample t-test as well as the Mann-Whitney U test. Continuous variables were defined as mean [+ or -] standard deviation, while categorical variables were identified as percentages. To test whether there was a difference in BDNF levels between the ADHD subtypes (a triple variable), the Kruskal-Wallis analysis was performed. The WISC-R scores, CBCL scores, the class children were attending, age, number of children in the family in the ADHD and control groups and their correlations with BDNF levels were determined by the Pearson's correlation test. With covariance analysis, the difference between sexes was prevented from being a confounding factor. Statistical significance was determined at p < 0.05.


The study group consisted of 31 children diagnosed with ADHD and 30 healthy controls between ages 6 and 12 yrs. The mean age of the ADHD cases recruited was 8.45 [+ or -] 1.57 and of healthy controls 8.87 [+ or -] 1.92 years. No statistically significant difference was found between the ADHD and control groups regarding age (p>0.05). 26 of the ADHD cases (83.9%) were male and 5 (16.1%) were female. 11 of the healthy controls (36.7%) were male and 19 (63.3%) were female.

The statistically significant difference was found between children diagnosed with ADHD and control groups regarding gender (p = 0.000). The average education of mothers (p = 0.632), average education of fathers (p = 0.505), marital status of the mothers (p = 0.354), family income (p = 0.418), and the number of siblings (p = 0.178) were similar in both groups.

The mean WISC-R verbal scores of the ADHD cases and healthy controls were 93.10 [+ or -] 12.59 and 95.00 [+ or -] 9.87, respectively. The mean WISC-R performance scores of the ADHD cases and healthy controls were 100.97 [+ or -] 18.09 and 96.43 [+ or -] 11.54, respectively. The mean WISC-R total scores of the ADHD cases and healthy controls were 96.45 [+ or -] 14.40 and 95.00 [+ or -] 10.03, respectively. No statistically significant differences were found between the ADHD and control groups regarding the mean WISC-R verbal, performance and total scores (p > 0.05).

The distributions of ADHD subtypes, comorbidity and the CGI-ADHD-severity scale, Du Paul's ADHD Rating Scales and the Conners' Teacher Rating Scale are shown in Table 1.

The average subscale scores of the CBCL applied to the case and control groups are presented in Table 2. Overall, average subscale scores were found to be statistically higher in the patient group compared to the control group (p<0.05).

In the present study, the types of ADHD were found to be 12.9% cases with attention deficit predominant type, 16.1%--hyperactivity predominant type and 71.0% with combined type. 67.7% of the cases had one or more comorbidities. Since mood disorders, psychotic disorders and mental retardation were exclusion criteria in our ADHD cases, common comorbid diagnoses were oppositional defiant disorder (ODD), anxiety disorders (separation anxiety disorder, specific phobia, social anxiety disorder), enuresis nocturna and tic disorders, in order of frequency.

Serum BDNF Levels

No statistically significant difference was found between the BDNF levels of ADHD cases and the control group (t-test, p = 0.885), (Table 3).

The ADHD cases and control group were statistically similar regarding age but different by gender. With covariance analysis, the difference between sexes was prevented from being a confounding factor. When matched for gender, ANCOVA showed no significant difference the between groups.

Regarding gender analysis in control and case groups, the Mann-Whitney U test showed no significant difference between males and females for BDNF levels (Table 3). Besides, within both groups, no significant difference was found between sexes (Table 4).

The correlation between clinical features of ADHD cases and BDNF levels is shown in Table 5.

In ADHD cases, no statistically significant association was found between serum BDNF levels and ADHD subtypes (p<0.093). However, although there was no statistically significant difference, serum BDNF levels were found to be lower in children with attention deficit predominant ADHD compared to children with combined type ADHD. No statistically significant difference was found within the ADHD group when serum BDNF levels were compared regarding comorbid diagnoses (p<0.300).


As for the correlation of age and WISC-R scores in ADHD and control groups with serum BDNF levels, no statistically significant difference was found between the two groups (p>0.05).

No significant relation was found between serum BDNF levels in the case and control groups and CBCL subscore points (p<0.05). The CBCL scale scores in case and control groups and its correlation with serum BDNF levels are presented in Table 6.

No statistically significant relationship was found between impairment severity (CGI-ADHD-severity scale), Du Paul's and Conners' scale scores in ADHD cases and serum BDNF levels (p<0.05). The impairment severity in ADHD cases (CGI-ADHD-severity scale), Du Paul's and Conners' scale scores and their correlations with BDNF levels are presented in Table 7.


In the present study, no statistically significant difference was found between children diagnosed with ADHD and control group for BDNF levels. Regarding the analysis of gender and BDNF levels in both groups, no statistically significant difference was found when males and females were compared. Also, no significant difference was found within the two groups regarding gender.

As far as we know, the present study is the first study to investigate serum BDNF levels in peripheral blood in children diagnosed with ADHD and having no history of former psychiatric medication. The only study that compared ADHD cases and healthy controls regarding BDNF levels was conducted by Shim et al. The authors found that plasma BDNF levels were significantly higher in the ADHD cases compared to controls (18). In the study conducted by Shim et al., the groups consisted of 41 drug naive ADHD patients and 107 normal controls within the age range of 6 and 14 years (18). The groups were age-matched, similar to the present study, but it was stated that there was a statistically significant difference regarding gender distribution, as observed in the present study. When the groups were age- and gender-standardized, the covariance analysis showed that the mean plasma BDNF levels were significantly higher in the children diagnosed with ADHD (840.5 [+ or -] 53.5 pg/mL) when compared to healthy controls (575.9 [+ or -] 32.2 pg/mL) (18). Additionally, similar to the present study, no significant difference in plasma BDNF levels was found between the genders within both ADHD and control groups (18).

In the present study, no significant relation was observed between serum BDNF levels in the patient and control groups and CBCL subscore points, and no statistically significant relationship was found between impairment severity (CGI-ADHD-severity scale), Du Paul's and Conners' scale scores in ADHD cases and serum BDNF levels. However, Shim et al. found that there was a significant positive correlation between attention deficit symptom severity and plasma BDNF levels. The results of the present study do not support these results.

BDNF is the most common neurotrophic factors and is found in the central and peripheral nervous systems in high quantities. It has been shown that BDNF may pass the blood-brain barrier bilaterally (21,27) and that there is a significant correlation between serum and cortical BDNF levels in mice (28). There are studies proposing that serum BDNF levels are 100 times (29) or 200 (19) times higher than the plasma ones. The majority of serum BDNF originates from thrombocytes. It has been shown that BDNF is not produced in human pre-megacaryocyte cells and that the thrombocytes store BDNF from external resources (20). The potential resources of BDNF are vascular endothelial and smooth muscle cells (30,31,32). Other potential resources are activated macrophages or lymphocytes (33,34,35). Since BDNF passes the blood-brain barrier bilaterally, it has been hypothesized that an important portion of its serum levels originates from neurons and glial cells (21,28). Therefore, the BDNF stored in thrombocytes possibly originates from brain cells. When taking into consideration the grand differences between serum, thrombocyte and plasma BDNF levels and that the serum BDNF levels are affected, while the plasma ones are less affected by the BDNF stored in the thrombocytes, it may be concluded that plasma BDNF reflects current BDNF levels from central BDNF levels and that serum BDNF levels do not. From this point of view, the presence of no difference between ADHD and control groups in the present study assessing serum levels and the significant difference between case and control groups in the study of Shim et al. that measured plasma levels may indicate that serum BDNF is a non-specific peripheral marker, while plasma BDNF level is a marker in the pathogenesis of the illness (18). On the other hand, bearing in mind that BDNF passes the blood-brain barrier bilaterally (21,27), there was a significant correlation between serum and cortical BDNF levels in mice (28) and that thrombocyte cells have a half life of 11 days, so that the effect size would be small, it may be concluded that serum BDNF might reflect the central BDNF From this point of view, our study does not support the hypothesis that BDNF plays a role in the etiology of ADHD. When taking into consideration that it has not been yet enlightened by which means the measurement of BDNF (complete blood, serum, plasma, and thrombocytes) is the accurate and most reliable procedure, one of the main limitations of this study is that the BDNF levels were studied only in the serum.

In the present study, we observed no statistically significant correlation between serum BDNF levels and ADHD subtypes. However, although there was no statistically significant difference, serum BDNF levels were found to be lower in children diagnosed with attention deficit predominant type ADHD when compared to children diagnosed with combined type ADHD. Tsai proposed a speculative hypothesis that decreased BDNF activity in the midbrain region may play a role in the therapeutic action and pathogenesis of ADHD (10). The result of the present study could support the hypothesis.

BDNF also seems to be involved in the pathophysiology of depression (36) and has been recognized as a mediator of the antidepressant drug response (37). Because of these data, we excluded the affective disorders in the present study. In addition, no statistically significant difference was found within the ADHD group when serum BDNF levels were compared regarding comorbid diagnoses.

In a study evaluating the age-related changes in serum BDNF levels in healthy individuals, it was found that serum BDNF levels within first 10 years were same as in 30-39 yrs which is accepted as the adult level. However, the BDNF levels significantly started to decrease within 10-19 yrs. No significant difference was found in serum BDNF levels regarding gender within any age range (38). In an adult study, effects of age, gender and weight on serum, thrombocyte and plasma BDNF levels were evaluated in 140 healthy adults within age range 20-60 yrs. The authors observed that plasma BDNF decreased as age or weight increased. In Lommatzsch et al. (1999) study, the female subjects had lower thrombocyte BDNF levels compared to male subjects. However, no difference was detected in plasma BDNF levels between the genders (31). Within this context, to reduce the confounding effect of different age and developmental phases on neurotrophins, all children recruited in our study were chosen from preadolescence period forming a narrow age range. A prior study has shown that BDNF levels decrease with body weight (31). As for this reason, another limitation of the study is that the body weights of the children recruited were not measured.

Because higher serum BDNF levels were shown to exist in patients with mental retardation (39), WISC-R was applied to ADHD and control groups and no significant difference regarding intelligence quotations was found when the groups were compared.

In preclinical studies, it was shown that exercise stimulates neurogenesis and increases brain BDNF levels. In another study conducted on healthy individuals, it was found that physical activity increased BDNF levels (40). When these findings are taken into account, another limitation of this study is that the exercises were not standardized.

In conclusion, our results indicate no change of serum BDNF levels in drug-naive children with ADHD. Further large studies are required to investigate the serum BDNF levels in children with ADHD. The accurate interpretation of BDNF levels in the blood, the factors affecting them and the reliable measurement source of the peripheral blood BDNF and its method need to be enlightened.

Conflict of interest

The authors reported no conflict of interest related to this article.

Cikar catismasi:

Yazarlar bu makale ile ilgili olarak herhangi bir cikar catismasi bildirmemislerdir.

DOI: 10.4274/npa.y5958


(1.) Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. Biederman J, Rohde LA: The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression: Analysis. Am J Psychiatry 2007; 164:942-948.

(2.) Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. Molecular genetics of Attention-Deficit/Hyperactivity Disorder. Biol Psychiatry 2005; 57:1313-1323.

(3.) Bobb AJ, Castellanos FX, Addington AM, Rapoport JL. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet 2005; 132:109-125.

(4.) Sen S, Duman R, Sanacora C. Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications. Biol Psychiatry 2008; 64:527-532.

(5.) Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP Lindsay RM. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350:230-232.

(6.) Spina MB, Squinto SIP Miller J, Lindsay RM, Hyman C. Brain derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 1992; 59:99-106.

(7.) Hyman C, Juhasz M, Jackson C, Wright P Ip NY, Lindsay RM. Overlapping and distinct actions of the neurotrophins BDNF, NT-3 and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 1994; 14:335-347.

(8.) Hung HC, Lee EH. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 1996; 41:14-26.

(9.) Solanto MV. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 2002; 130:65-71.

(10.) Tsai SJ. Attention-deficit hyperactivity disorder may be associated with decreased central brain-derived neurotrophic factor activity: clinical and therapeutic implications. Med Hypotheses 2007; 68:896-899.

(11.) Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T. Implication of brain- derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 2003; 119:767-775.

(12.) Meredith GE, Callen S, Scheuer DA. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 2002; 949:218-227.

(13.) Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539-7547.

(14.) Gainetdinov RR, Caron MG. Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40:380-382.

(15.) Fumagalli F, Racagni G, Colombo E, Riva MA. BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry 2003; 8:898-899.

(16.) Kernie SG, Liebl DJ, Parada LF BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000; 19:1290-1300.

(17.) Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, Lechan RM, Jaenisch R. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 2001; 15:1748-1757.

(18.) Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, Kim YK. Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1824-1828.

(19.) Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF Bennett L, Miller JA, Welcher AA. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995; 6:465-471.

(20.) Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, Sun B, Tandon NN. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87:728-734.

(21.) Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37:1553-1561.

(22.) Kaufman J, Birmaher B, Brent DA, Ryan ND, Rao U. K-SADS-PL. J Am Acad Child Adolesc Psychiatry 2000; 39:1208.

(23.) American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text revision (DSM-IV-TR). Washington DC; 2000.

(24.) Achenbach TW. Manual for the child behavior checklist/4-18 and 1991 Profile, Burlington, VT: University of Vermont; Department of Psychiatry; 1991.

(25.) DuPaul GJ. Parent and teacher rating of ADHD symptoms: Psychometric properties in a community-based sample. J Clin Child Psychol 1991; 20:245-253.

(26.) Conners CK. Conners abbreviated symptom questionnaire. North Tonawanda NY: Multi Health Systems; 1994.

(27.) Poduslo JF Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF CNTF NT-3, BDNF. Brain Res Mol Brain Res 1996; 36:280-286.

(28.) Karege F Schwald M, Cisse M. Postnatal developmental profile of brainderived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328:261-264.

(29.) Radka SF Holst PA, Fritsche M, Altar CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996; 709:122-301.

(30.) Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D, Sharif S, Kaplan DR, Tsoulfas P Parada L, Toran-Allerand CD, Hajjar DPP Hempstead BL. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 1995; 147:309-324.

(31.) Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV, Paus R, Fischer A, Lewin GR, Renz H. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol 1999; 155:1183-1193.

(32.) Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN, Sun B. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000; 470:113-137.

(33.) Braun A, Lommatzsch M, Mannsfeldt A, Neuhaus-Steinmetz U, Fischer A, Schnoy N, Lewin GR, Renz H. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999; 21:537-546.

(34.) Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F Increased brain-derived eurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol 2003; 57:493-497.

(35.) Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189:865-870.

(36.) D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4:183-194.

(37.) Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege IF Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51:234-238.

(38.) Katoh-Semba R, Wakako R, Komori T, Shigemi H, Miyazaki N, Ito H, Kumagai T, Tsuzuki M, Shigemi K, Yoshida F Nakayama A. Age-related changes in BDNF protein levels in human serum: differences between autism cases and normal controls. Int J Dev Neurosci 2007; 25:367-372.

(39.) Miyazaki K, Narita N, Sakuta R, Miyahara T, Naruse H, Okado N, Narita M. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev 2004; 26:292-295.

(40.) Tang SW, Chu E, Hui T, Helmeste D, Law C. Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett 2008; 431:62-65.

Enis SARGIN [1], Aynur PEKCANLAR AKAY [1], Halil RESMI [2], Sevay ALSEN CENGIZHAN [1], Handan OZEK [1], Hulya ELLIDOKUZ [3], Suha MIRAL [1], Esmahan ORCIN [1]

[1] Dokuz Eylul University School of Medicine, Department of Child and Adolescent Psychiatry, Izmir, Turkey

[2] Dokuz Eylul University School of Medicine, Department of Biochemistry, Izmir, Turkey

[3] Dokuz Eylul University School of Medicine, Department of Preventive Oncology, Izmir, Turkey

Address for Correspondence/Yazism a Adresi: Dr. Aynur Pekcanlar Akay, Dokuz Eylul University School of Medicine, Department of Child and Adolescent Psychiatry, Izmir, Turkey Phone: +90 232 412 35 59 E-mail:

Received/Gelis tarihi: 26.12.2010 Accepted/Kabul tarihi: 06.07.2011
Table 1. Clinical features of children diagnosed with ADHD

 CASE GROUP (n=31)

 n (%)


Attention deficit predominant type 4 12.9
Hyperactivity predominant type 5 16.1
Combined type 22 71.0


Yes 21 67.7
No 10 33.3


Medium severity 5 16.1
Definite severity 14 45.2
Severe 12 38.7
Much severe 0 0
 mean [+ or -] SD range

Mothers 27.29 [+ or -] 7.11 (9-39)
Fathers 23.10 [+ or -] 8.93 (1-41)
Teachers 26.32 [+ or -] 8.18 (9-42)


Conduct 30.87 [+ or -] 8.81 (13-46)
Inattentive and Passive 33.48 [+ or -] 8.51 (16-51)
Hyperactivity 32.42 [+ or -] 8.78 (15-48)
10-Item Hyperactivity 27.13 [+ or -] 8.75 (12-48)

Table 2. The distribution of CBCL scores of case and control groups

 GROUP (n=31) GROUP (n=30)
 mean [+ or -] SD mean [+ or -] SD

CBCL subtests

Withdrawn 63.68 [+ or -] 11.76 53.17 [+ or -] 4.19
Somatic complaints 64.32 [+ or -] 13.13 52.80 [+ or -] 4.44
Anxious/depressed 68.84 [+ or -] 8.93 56.67 [+ or -] 5.62
Social problems 66.23 [+ or -] 11.40 56.20 [+ or -] 6.36
Thought problems 69.29 [+ or -] 13.44 62.00 [+ or -] 8.46
Attention problems 71.90 [+ or -] 10.18 53.03 [+ or -] 3.88
Delinquent behavior 67.90 [+ or -] 12.69 59.67 [+ or -] 7.24
Aggressive behavior 68.23 [+ or -] 10.86 51.17 [+ or -] 2.48
Internalizing problems 68.48 [+ or -] 10.97 52.60 [+ or -] 7.87
Externalizing problems 68.39 [+ or -] 10.67 49.70 [+ or -] 6.99
Total problems 72.52 [+ or -] 11.00 54.07 [+ or -] 8.00


CBCL subtests

Withdrawn 0.000
Somatic complaints 0.000
Anxious/depressed 0.000
Social problems 0.000
Thought problems 0.014
Attention problems 0.000
Delinquent behavior 0.003
Aggressive behavior 0.000
Internalizing problems 0.000
Externalizing problems 0.000
Total problems 0.000

Table 3. The comparison of levels of serum BDNF in
children diagnosed with
ADHD and control group


 n mean [+ or -] SD

BDNF 31 2124.45 [+ or -] 1044.31
MALE 26 2233.40 [+ or -] 1060.23
FEMALE 5 1557.90 [+ or -] 821.91


 n mean [+ or -] SD

BDNF 30 2157.63 [+ or -] 694.94
MALE 11 2196.40 [+ or -] 632.76
FEMALE 19 2135.19 [+ or -] 744.44


BDNF 0.885 *
MALE 0.855 **
FEMALE 0.145 **

* T-test was used

** The Mann-Whitney U test was used

Table 4. Comparison of serum BDNF levels in ADHD
cases and control groups according to gender

 BDNF levels p
 mean [+ or -] SD


Male (n = 26) 2233.40 [+ or -] 1060.23 0.179
Female (n = 5) 1557.90 [+ or -] 821.91


Male(n = 11) 2196.40 [+ or -] 632.76 0.983
Female(n = 19) 2135.19 [+ or -] 744.44

The Mann-Whitney U test was used

Table 5. The comparison of serum BDNF levels among children
diagnosed with ADHD; ADHD subtypes and the presence of comorbidity

 BDNF levels p
 mean [+ or -] SD


Attention deficit 1222.45 [+ or -] 955.39 0.093 *
 predominant type (n = 4)
Hyperactivity predominant 1768.22 [+ or -] 633.44
 type (n = 5)
Combined type (n = 22) 2369.41 [+ or -] 1050.29


Yes (n = 21) 2271.62 [+ or -] 1153.50 0.300 **
No (n = 10) 1815.37 [+ or -] 722.35

* The Kruskal-Wallis test was used.

** The Mann-Whitney U test was used

Table 6. The correlation between the CBCL scale scores and
serum BDNF levels in case and control groups

 Correlation with BDNF

 Case(n = 31) Control (n = 30)

 r p r p
CBCL subtests
Withdrawn -0.094 0.614 -0.038 0.842
Somatic complaints -0.064 0.733 -0.051 0.787
Anxious/depressed 0.012 0.948 0.236 0.210
Social problems 0.078 0.675 0.125 0.510
Thought problems 0.045 0.810 0.191 0.311
Attention problems 0.053 0.779 0.105 0.581
Delinquent behavior 0.063 0.735 0.251 0.180
Aggressive behavior -0.009 0.961 0.028 0.883
Internalizing problems -0.080 0.668 0.146 0.443
Externalizing problems 0.027 0.886 0.197 0.296
Total problems 0.035 0.852 0.217 0.249

Table 7. The impairment severity in ADHD cases
(CGI-ADHD-severity scale), Du Paul's and Conners'
Scale Scores and their correlation with BDNF levels

 with BDNF

 r p

 (CGI)-ADHD severity
Du Paul mother score (n=31) 0.236 0.200
Du Paul father score (n=31) 0.227 0.228
Du Paul teacher score (n=31) 0.072 0.700
Conners' behavior score (n=31) 0.303 0.098
Conners' hyperactivity score (n=31) 0.163 0.381
Conners' attention deficiency score(n=31) 0.254 0.168
Conners' hyperactivity index(n=31) 0.243 0.187
COPYRIGHT 2012 Galenos Yayinevi Tic. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article/Arastirma Makalesi
Author:Sargin, Enis; Akay, Aynur Pekcanlar; Resmi, Halil; Cengizhan, Sevay Alsen; Ozek, Handan; Ellidokuz,
Publication:Archives of Neuropsychiatry
Article Type:Report
Date:Jun 1, 2012
Previous Article:Personality and primary dysmenorrhea: a study using a five-factor model in Chinese university women/Kisilik ve primer dismenore: Cinli universiteli...
Next Article:Validity and reliability of the [QIDS-SR.sub.16]-Turkish in comparison with BDI-II-Turkish among young outpatient sample of Turkish university...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters